Neurocrine Biosciences
NBIX
#1532
Rank
A$20.84 B
Marketcap
A$209.09
Share price
2.52%
Change (1 day)
-5.16%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): A$6.63

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$6.41. In 2024 the company made an earnings per share (EPS) of A$5.03 an increase over its 2023 EPS that were of A$3.78.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$6.6331.98%
2024A$5.0333.07%
2023A$3.7857.76%
2022A$2.3969.47%
2021A$1.41-78.21%
2020A$6.48990%
2019A$0.5981.82%
2018A$0.33-113.5%
2017A-$2.420.62%
2016A-$2.4157.28%
2015A-$1.5325.61%
2014A-$1.2218.84%
2013A-$1.03-1085.71%
2012A$0.10

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Repligen
RGEN
A$0.04461-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.63-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
A-$44.46-793.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$30.51 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$2.01-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$2.56-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$2.54-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$3.02-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA